ROQ vs. RLM, NSCI, BVX, APTA, GENF, FAB, ONC, CIZ, IXI, and TCF
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Realm Therapeutics (RLM), NetScientific (NSCI), BiVictriX Therapeutics (BVX), Aptamer Group (APTA), Genflow Biosciences (GENF), Fusion Antibodies (FAB), Oncimmune (ONC), Cizzle Biotechnology (CIZ), IXICO (IXI), and Theracryf (TCF). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
Roquefort Therapeutics (LON:ROQ) and Realm Therapeutics (LON:RLM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
Realm Therapeutics received 193 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Realm Therapeutics has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Realm Therapeutics has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Realm Therapeutics' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.
1.7% of Roquefort Therapeutics shares are owned by institutional investors. 60.4% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Roquefort Therapeutics had 1 more articles in the media than Realm Therapeutics. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Realm Therapeutics. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Realm Therapeutics'average media sentiment score.
Summary
Realm Therapeutics beats Roquefort Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 2/14/2025 by MarketBeat.com Staff